| |
Main Products Profiles
 |
Atimos® /Forair® is a pressurised metered dose inhaler solution formulation of formoterol fumarate, indicated in the long–term symptomatic treatment of persistent to
severe asthma in patients |
requiring regular bronchodilator therapy in combination with
long-term anti-inflammatory therapy.
Formoterol is a highly 2 selective adrenoreceptor agonist that has a rapid onset of action (within 5 minutes post dose) and maintains a bronchodilatory effect for up to 12 hours. Based on its duration of action, formoterol has been classified as a long- acting 2 agonist (LABA). Formoterol has been developed by Chiesi as a new metered dose inhaler (MDI) using the innovative Modulite ® technology. Formoterol Modulite® has been developed with a high extra-fine (MMAD 0.8 µm) fraction to optimise the pulmonary distribution profile. In fact, drug delivery in both asthma and COPD has to be targeted to both central and peripheral airways, thus enabling the disease to be treated uniformly. Formoterol Modulite has been formulated to allow the ideal delivery of drug throughout the bronchial tree, exactly where it is needed.
Thanks to the flexibility of Modulite® in tailoring the generated aerosol cloud, no dose adjustments are required, supporting a seamless transition from currently available formoterol formulations. This means that the dosage of formoterol Modulite® exactly matches the dose of formoterol in other formulations such as Foradil Aerolizer®.
Atimos® /Forair® is currently being marketed in Italy, Germany, France, Greece and the United Kingdom. |
| |
 |
Bramitob® (tobramycin) is an aminoglycoside antibiotic, developed by Chiesi in a new formulation
(nebulisation solution) for the long-term management of chronic pulmonary infection due to Pseudomonas aeruginosa in Cystic Fibrosis patients. |
Bramitob® single-dose vials of 4 mL (75 mg/mL) preservative
free sterile nebulisation solution are administered by inhalation and are formulated to improve
local tolerability.
Tobramycin has been investigated in several clinical trials, including large, placebo-controlled studies. Aerosolised tobramycin has demonstrated its effectiveness in improving lung function, reducing hospitalisation and intravenous antibiotic use in CF patients. Bramitob® has been registered and marketed in Italy since April 2006, and soon will also be available in other European Markets (UK, Ireland, Germany, Spain, Portugal, France, Greece, , Slovakia, Poland, Hungary, Czech Republic and Austria). |
| |
 |
Brexin® (piroxicam betadex - PBC) is a successful example of the clinical application of the Nobel
Prize winning host-guest technology whereby the host, a starch derivative known as ß-cyclodextrin, |
solubilises the guest, an anti-inflammatory drug known as piroxicam, thus enhancing the analgesic properties of the active ingredient.
Piroxicam betadex – PBC is indicated for the treatment of painful conditions and inflammation in rheumatic diseases (i.e.: rheumatoid arthritis, osteoarthritis), musculo-skeletal conditions (i.e.: tendonitis, bursitis, and post-traumatic pain), post-operative pain, and primary dysmenorrhoea.
After 18 years of success since its launch in Italy, PBC is marketed in 45 countries in South America, Europe, Asia and Africa. |
| |
 |
Clenil® (beclometasone dipropionate) is an inhaled corticosteroid indicated for the treatment
of asthma. Available in various |
pharmaceutical forms (solution for nebulisation, pressurised metered dose
inhaler, dry powder inhaler), Clenil is marketed in Italy, France and other European Countries. Recently, the product was launched in the UK with the trademark Clenil Modulite®.
Launched in 1979 in Italy, Clenil represents one of the most successful products for the Chiesi Group. In 2002 an innovative sterilization process, known as “Blow Fill Seal” was implemented. |
| |
 |
Clipper® (beclometasone dipropionate) is an oral, once daily corticosteroid indicated for the treatment
of mild to moderate ulcerative colitis in active phase together with 5-ASA therapy. |
| Clipper is available in gastro-resistant prolonged release tablets allowing a local delivery of the drug at the mucosa of the distal ileum and proximal colon, where the inflammatory process occurs, thus exerting a regional antinflammatory effect. In randomised controlled clinical trials in patients with mild to moderate ulcerative colitis, Clipper therapy improved clinical symptoms, induced remission and improved endoscopic outcomes. Currently, Clipper is marketed in Italy. |
| |
 |
Curosurf® (poractant alfa) is an intratracheal suspension used by healthcare professionals for the
prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants. |
The active ingredient of this natural surfactant is the phospholipid fraction obtained from porcine lung.
In adults, but also in term babies, surfactant lines the lungs and stops them from sticking together making normal breathing possible. However premature babies can be born with little or no surfactant, and develop RDS. The introduction of surfactant replacement therapy has contributed to the dramatic decrease of mortality in the premature: in the 1980s a baby born at around 28 week gestational age had a 50-70% survival rate while nowadays that same baby has a 90% chance of survival.
Since its first introduction in 1992 it has been estimated that more than 650,000 premature babies have
been treated with Curosurf®. Good clinical results together with an excellent safety profile made surfactant replacement therapy with Curosurf® the reference standard treatment. Global IMS data acknowledges that Curosurf has over 46% market share in sales, and places it as the leading surfactant in the total lung surfactant market worldwide. Curosurf® is now marketed throughout the world in over 50 different countries. |
| |
 |
Foster® is an extrafine formulation of the combination of beclometasone dipropionate (BDP) 100 micrograms
and formoterol fumarate (F) 6 micrograms, delivered via pressurised metered dose inhaler (pMDI) using an HFA propellant. |
The extrafine formulation allows Foster® to have uniform lung distribution and high lung deposition. The drug has been demonstrated to be safe and effective in patients with moderate to severe persistent asthma. The prescribed dosage is 1 to 2 puffs twice daily.
The product was launched in Germany in October 2006 as Foster ® (by the Local Market Company
Asche Chiesi) and Inuvair (by Chiesi`s co - marketer UCB) and has just been mutually approve
in fifteen European countries and enrolment in the clinical trial in COPD is in progress. |
| |
 |
Iperten® – Maniper® – Manivasc® – Artedil® Manidipina, a third-generation dihydropyridine calcium
antagonist, is a first-line treatment option for patients with essential mild-to-moderate hypertension. Manidipine is able to block the entry of calcium into the arteriolar muscle cells, thus strongly counteracting the vasoconstriction always present in the hypertensive patient. |
This compound is an effective antihypertensive drug with a good tolerability profile and also has beneficial effects on renal function.
Unlike other conventional Ca-antagonists, manidipine is also able to vasodilate the renal efferent arterioles, in addition to the afferent ones, consequently showing a superior nephroprotective profile. Furthermore, due to its characteristic properties, manidipine shows, among Ca-antagonists, the lowest incidence of ankle oedema which is one of the most frequent adverse effects of this drug class.
Manidipine is manufactured in tablets containing 10 or 20 mg of drug and is administered once daily, preferably in the morning after breakfast. Manidipine was launched first in Italy in 1996 with the
brand name Iperten®.
Today, manidipine is commercialized with different brand names, besides Italy, in
the following countries: Spain – Artedil®; France, Tunisia, and Morocco – Iperten®; Germany and Greece – Manyper®; Brazil – Manivasc®.
|
| |
 |
Vivace® is a new oral, once-daily, fixed combination of the third-generation dihydropyridine calcium
channel blocker manidipine (10 mg) with the nonsulfhydryl ACE inhibitor delapril (30 mg). |
The drug is a particularly useful alternative to the available combination therapies for hypertension as it combines two well-tolerated agents of the calcium channel blocker and ACE inhibitor classes that not only effectively lower blood pressure, but also provide the potential for additional protection of the target organs, such as the heart and kidney.
Vivace represents a valuable therapeutic option for treating hypertension, in particular in patients with type 2 diabetes and in those at high risk of cardiovascular disease.
The Vivace fixed dose combination is indicated in patients whose blood pressure is not adequately controlled by delapril or manidipine alone. The product was launched in Brazil in March 2006 as Hipertil® and in Germany in April 2006. In the near future, it will be launched in Greece and Spain.
|
|
|
